India needs stronger regulations to remain leader in generic drugs: WHO expert

Speaking to ANI, Soumya Swaminathan said, “I think it is going to be very important for the reputation and ultimately for India to remain as a leader in the field of generic medicine and vaccines beyond doubt.” To prove that we have a very strong regulatory system in place.”

Dr. SwaminathaniPresent in Pune for the 23rd Annual General Meeting of the Vaccine Manufacturers Network of Developing Countries (DCVMN), said that pharmaceutical contamination is a significant problem that needs to be addressed.

India had sought more information from WHO about the initial illness, symptoms and care given to them. Gambian Children He died after allegedly consuming contaminated cough syrup made by a company with a Sonipat address.

“WHO actually provided the report based on the investigation that was done to prove that it was due to diethylene glycol (DEG) contamination, this is a serious issue, I think it should be taken very seriously ,” He said.

“We have central and state regulators. We need to look at the rules of operation and see how we harmonize them,” he said.

The expert claimed that drug regulators from different states can actually cooperate and conduct cross-inspections on goods imported and exported within the country.

Soumya Swaminathan said, “Therefore, I feel that there have already been several recommendations to strengthen and identify some of the weaknesses in the existing system and strengthen it.”

Following the meeting of the Expert Committee on the “Adverse Events” report on the deaths of kids in gambiaThe DCGI wrote to the WHO last week and said that the clinical characteristics and treatment received by the children were shared to the point that they were insufficient to determine the aetiology.

(with inputs from ANI)